Related Experiment Video
Updated: May 23, 2025
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
Published on: July 5, 2024
Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke Hizuka1, Shin-Ichiro Hagiwara1, Ryutaro Saura1
1Department of Gastroenterology, Nutrition, and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan.
Insights
Acotiamide showed effectiveness in treating pediatric functional dyspepsia (FD), with over half of young patients experiencing symptom relief. This drug may be a valuable option for children with FD across all subtypes.
Area of Science:
- Pediatric Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Functional dyspepsia (FD) is a common chronic upper abdominal disorder without a clear organic cause.
- Acotiamide is an effective treatment for adult FD, but its pediatric efficacy is not well-established.
Purpose of the Study:
- To assess the efficacy of acotiamide in pediatric patients diagnosed with functional dyspepsia.
- To determine if acotiamide is a viable treatment option for children experiencing FD symptoms.
Main Methods:
- A retrospective analysis was performed on 33 pediatric patients (<16 years) treated with acotiamide.
- Data was collected from a single children's hospital between August 2013 and March 2022.
Main Results:
- Symptomatic improvement was noted in 57.6% of pediatric patients after one month of acotiamide treatment.
- Improvement rates varied by FD subtype (epigastric pain syndrome, postprandial distress syndrome, overlap), but differences were not statistically significant (p=0.213).
- Two patients discontinued treatment due to abdominal pain; no serious adverse events were reported.
Conclusions:
- Acotiamide demonstrates efficacy in pediatric functional dyspepsia, mirroring adult study findings.
- Acotiamide presents a potential therapeutic option for pediatric FD, applicable across its various subtypes.
Purpose:
Functional dyspepsia (FD) is a chronic disorder characterized by upper abdominal symptoms in the absence of an identifiable organic cause. Although the efficacy of acotiamide has been demonstrated in adults with FD, its effectiveness in pediatric patients remains unclear. This study aimed to evaluate the efficacy of acotiamide in pediatric patients with FD.
Methods:
We conducted a retrospective analysis of 33 patients with FD, aged <16 years, who received acotiamide at a single children's hospital between August 2013 and March 2022.
Results:
Symptomatic improvement was observed in 57.6% (19/33) of patients one month after acotiamide administration. The improvement rates were 63.6%, 20.0%, and 66.7% among patients with epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), and overlap PDS-EPS, respectively. No statistically significant differences in symptomatic improvement rates were noted among the subtypes (p=0.213). Two patients discontinued acotiamide because of abdominal pain, but no serious adverse events were reported.
Conclusion:
Acotiamide demonstrated efficacy in pediatric FD, which is consistent with previously reported outcomes in adults. Acotiamide may be a beneficial treatment option for pediatric FD across all subtypes.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists